Molbio Diagnostics Surges 83% Since Listing: Motilal Oswal Issues 'Buy' Rating

Source: Mint Markets
Arth Insight · What this means for your wallet
- Your initial investment in Molbio Diagnostics could have grown by over 80% if you participated in the IPO.
- The stock's rapid rise suggests high investor confidence, but also potential for price corrections.
- Motilal Oswal's 'Buy' rating indicates potential for further gains, but past performance is not a guarantee of future returns.
Molbio Diagnostics has delivered massive returns of over 80% within two months of its stock market debut. Brokerage firm Motilal Oswal remains bullish on the stock, citing strong growth potential despite the recent price rally.
- ▸Molbio Diagnostics has gained 83% in less than two months since its August debut.
- ▸The stock rose from an IPO price of ₹807 to over ₹1,475.
- ▸Motilal Oswal has issued a 'Buy' recommendation despite the recent price surge.
- ▸The company is gaining traction due to its specialized point-of-care diagnostic solutions.
- ✓Molbio Diagnostics has gained 83% in less than two months since its August debut.
- ✓The stock rose from an IPO price of ₹807 to over ₹1,475.
- ✓Motilal Oswal has issued a 'Buy' recommendation despite the recent price surge.
- ✓The company is gaining traction due to its specialized point-of-care diagnostic solutions.
Molbio Diagnostics, a recent entrant to the Indian stock exchanges, has emerged as a top performer in the healthcare diagnostics space. Since its listing on August 17, the stock has surged by approximately 83%, climbing from its initial public offering (IPO) price of ₹807 to a current market price of ₹1,475.50.
Rapid Growth Post-Listing
The stock's performance is particularly notable given the short timeframe of less than two months. Investors who were allotted shares in the IPO have seen their capital nearly double. This rally reflects strong market confidence in the company's business model and its role in the point-of-care testing segment in India.
Why Motilal Oswal is Bullish
Despite the steep rise in valuation, domestic brokerage firm Motilal Oswal has maintained a positive outlook on the counter. The brokerage suggests that the company's unique positioning in the diagnostics market and its expanding footprint provide further room for upside. While the stock has already surpassed many initial expectations, the institutional interest suggests that the long-term growth story remains intact.
Market Context and Performance
The diagnostics sector in India has seen significant volatility and competition recently. However, Molbio's specialized focus has allowed it to carve out a niche. At the current price of ₹1,475.50, the market is pricing in sustained earnings growth and potential expansion into new testing categories. Retail investors should, however, note that such rapid gains often lead to periods of consolidation or profit-booking.
This report is for informational purposes only and does not constitute financial advice. Consult a SEBI-registered advisor before investing.
Some listings may be sponsored and Arth Vani may earn a referral fee. All information is for educational purposes only — verify terms and suitability with the provider before acting. Not financial advice.
Frequently Asked Questions
What was the IPO price of Molbio Diagnostics?
The IPO price of Molbio Diagnostics was ₹807 per share.
How much has the stock gained since its listing?
The stock has gained approximately 83% from its IPO price in less than two months.
What is the current recommendation for Molbio Diagnostics?
Brokerage firm Motilal Oswal has recommended a 'Buy' on the stock, citing further growth potential.
Join the Arth Vani channels
Daily news summaries, IPO & market alerts on Telegram and WhatsApp.
Because you read about Stock Market
IPOBreakingAirtel Payments Bank Eyes IPO in 3-4 Years, Targets ₹10,000 Crore Revenue
Airtel Payments Bank may launch an Initial Public Offering (IPO) within the next three to four years, according to Sunil Bharti Mittal. The bank aims to significantly expand its financial services business, targeting ₹10,000 crore in revenue and deposits, along with ₹1,000 crore in profit.
IPOBreakingRazorpay IPO Gets SEBI Nod: Fintech Aims to Raise ₹5,000 Crore
Fintech major Razorpay has received approval from SEBI for its initial public offering (IPO), five months after confidentially filing its draft documents. The company reportedly plans to raise approximately ₹5,000 crore (around $600 million) through the public issue.
BreakingSensex Recovers 400 Points from Lows as Nifty Reclaims 25,200 Mark
Indian equity benchmarks staged a strong recovery during intraday trading, with the Sensex bouncing back over 400 points from its daily lows. The Nifty 50 successfully climbed back above the crucial 25,200 level, signaling resilience despite initial volatility.
Related Stories
IPOBreakingAirtel Payments Bank Eyes IPO in 3-4 Years, Targets ₹10,000 Crore Revenue
Airtel Payments Bank may launch an Initial Public Offering (IPO) within the next three to four years, according to Sunil Bharti Mittal. The bank aims to significantly expand its financial services business, targeting ₹10,000 crore in revenue and deposits, along with ₹1,000 crore in profit.
IPOBreakingRazorpay IPO Gets SEBI Nod: Fintech Aims to Raise ₹5,000 Crore
Fintech major Razorpay has received approval from SEBI for its initial public offering (IPO), five months after confidentially filing its draft documents. The company reportedly plans to raise approximately ₹5,000 crore (around $600 million) through the public issue.
BreakingSensex Recovers 400 Points from Lows as Nifty Reclaims 25,200 Mark
Indian equity benchmarks staged a strong recovery during intraday trading, with the Sensex bouncing back over 400 points from its daily lows. The Nifty 50 successfully climbed back above the crucial 25,200 level, signaling resilience despite initial volatility.
IPOBreakingAnthropic IPO: Claude AI Maker Targets $64.4 Billion Fundraising in Mega Public Issue
Anthropic, the artificial intelligence startup behind the Claude chatbot, has commenced its IPO roadshow to raise up to $64.4 billion. The company plans to offer 825 million shares as it seeks to compete with industry leaders like OpenAI and Google.